Literature DB >> 22349479

[Dobutamine in severe heart failure. More questions than answers].

U Janssens1.   

Abstract

Entities:  

Year:  2012        PMID： 22349479     DOI： 10.1007/s00063-012-0077-2

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN： 2193-6218            Impact factor:   0.840


× No keyword cloud information.
  10 in total

1.  Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein.

Authors:  C Communal; K Singh; D B Sawyer; W S Colucci
Journal:  Circulation       Date:  1999-11-30       Impact factor: 29.690

Review 2.  Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Catherine L Tacon; John McCaffrey; Anthony Delaney
Journal:  Intensive Care Med       Date:  2011-12-08       Impact factor: 17.440

3.  Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries.

Authors:  Robb D Kociol; Bradley G Hammill; Gregg C Fonarow; Winslow Klaskala; Roger M Mills; Adrian F Hernandez; Lesley H Curtis
Journal:  Am Heart J       Date:  2010-11       Impact factor: 4.749

4.  In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).

Authors:  William T Abraham; Kirkwood F Adams; Gregg C Fonarow; Maria Rosa Costanzo; Robert L Berkowitz; Thierry H LeJemtel; Mei L Cheng; Janet Wynne
Journal:  J Am Coll Cardiol       Date:  2005-07-05       Impact factor: 24.094

5.  Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods.

Authors:  Alexandre Mebazaa; John Parissis; Raphael Porcher; Etienne Gayat; Maria Nikolaou; Fabio Vilas Boas; J F Delgado; Ferenc Follath
Journal:  Intensive Care Med       Date:  2010-11-18       Impact factor: 17.440

Review 6.  [Pathophysiology of heart failure today].

Authors:  Michael Böhm
Journal:  Herz       Date:  2002-03       Impact factor: 1.443

7.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.

Authors:  Alexandre Mebazaa; Markku S Nieminen; Milton Packer; Alain Cohen-Solal; Franz X Kleber; Stuart J Pocock; Roopal Thakkar; Robert J Padley; Pentti Põder; Matti Kivikko
Journal:  JAMA       Date:  2007-05-02       Impact factor: 56.272

Review 8.  [Acute heart failure: diagnosis and monitoring].

Authors:  U Janssens
Journal:  Dtsch Med Wochenschr       Date:  2009-06-04       Impact factor: 0.628

9.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

Authors:  F Follath; J G F Cleland; H Just; J G Y Papp; H Scholz; K Peuhkurinen; V P Harjola; V Mitrovic; M Abdalla; E-P Sandell; L Lehtonen
Journal:  Lancet       Date:  2002-07-20       Impact factor: 79.321

Review 10.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983
  10 in total
  1 in total

Review 1.  [Catecholamines: pro and contra].

Authors:  R Riessen; O Tschritter; U Janssens; M Haap
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-03-25       Impact factor: 0.840
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.